Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6051489 | 0.91 | GAA (0.36) | ALDH1A1GAATDP1 | |
| SCHEMBL14804671 | 0.89 | ALDH1A1 (0.38) | CYP1A2ALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL21318822 | 0.89 | ALDH1A1 (0.38) | CYP1A2ALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL1968887 | 0.86 | ALDH1A1 (0.42) | ALDH1A1GAATDP1 | |
| SCHEMBL8795 | 0.83 | CYP1A2 (0.52) | CYP1A2ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL11489562 | 0.83 | CYP1A2 (0.39) | CYP1A2ALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL329417 | 0.78 | CYP1A2 (0.52) | CYP1A2ALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL2029438 | 0.78 | TP53 (0.33) | — | |
| SCHEMBL11779604 | 0.77 | GAA (0.30) | GAATDP1 | |
| SCHEMBL8634269 | 0.77 | HSP90AA1 (0.46) | GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | CYP1A2 959/4885ALDH1A1 290/4885SMN1; SMN2 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.